Baumann P, Hiemke C, Ulrich S, Eckermann G, Kuss H L, Laux G, Müller-Oerlingenhausen B, Rao M L, Riederer P, Zernig G
Département de psychiatrie, CHUV, Université de Lausanne.
Rev Med Suisse. 2006 May 24;2(67):1413-8, 1420-2, 1424-6.
In psychiatry, therapeutic drug monitoring (TDM) is an established procedure for most psychotropic drugs. However, as its use in everyday clinical practice is far from optimal, the AGNP-TDM group has worked out consensus guidelines to assist psychiatrists and laboratories involved in drug analysis. Based on a thorough analysis of available literature, 5 levels of recommendation were defined with regard to TDM of psychoactive drugs, from 1) (strongly recommended) to 5) (not recommended). A list of indications for TDM, alone or in combination with pharmacogenetic tests is presented. Instructions are given with regard to preparation of TDM, analytical procedures, reporting and interpretation of results and the use of information for patient treatment. Using the consensus guideline will help to ensure optimal clinical benefit of TDM.
在精神病学领域，治疗药物监测（TDM）是大多数精神药物的既定程序。然而，由于其在日常临床实践中的应用远未达到最佳状态，AGNP-TDM小组制定了共识指南，以协助参与药物分析的精神科医生和实验室。基于对现有文献的全面分析，针对精神活性药物的TDM定义了5个推荐级别，从1）（强烈推荐）到5）（不推荐）。列出了TDM单独使用或与药物遗传学检测联合使用的适应证清单。给出了关于TDM准备、分析程序、结果报告与解读以及将信息用于患者治疗的说明。使用该共识指南将有助于确保TDM获得最佳临床效益。
